Sign in Subscribe
Machine learning

SAVANA Algorithm Revolutionizes Cancer Genomics Analysis

Strategic Insights

— 2 min read

Cancer genomics analysis is a complex task, and researchers have long struggled with identifying structural variations and copy number aberrations in long-read DNA sequencing data. To overcome this challenge, researchers at the European Bioinformatics Institute (EMBL-EBI) and Genomics England developed SAVANA, a machine learning algorithm that accurately identifies cancer-specific structural variations and copy number aberrations. SAVANA's unique design enables it to outperform standard analysis tools, reducing errors and providing a better understanding of tumour biology. The algorithm's rapid analysis and robust error correction capabilities make it well-suited for clinical use, and its applications in studying rare and aggressive bone cancer, osteosarcoma, have provided novel insights into how the disease evolves and progresses.

Key Takeaways:

  • SAVANA uses a machine learning algorithm to identify cancer-specific structural variations and copy number aberrations in long-read DNA sequencing data.
  • The algorithm was developed and tested across 99 human tumour samples by researchers at EMBL-EBI and Genomics England.
  • SAVANA significantly reduces false-positive results and provides accurate interpretations of tumour biology, enabling clinicians to make informed decisions.
  • The algorithm's rapid analysis and robust error correction make it well-suited for clinical use, allowing for the accurate detection of structural variants and copy number aberrations.
  • SAVANA has been used to study osteosarcoma, a rare and aggressive bone cancer, providing novel insights into how the disease evolves and progresses.
  • The algorithm's performance was comparable to current clinical standards, and its results revealed additional cancer-relevant alterations.
  • SAVANA has the potential to improve diagnostic accuracy and support personalized cancer treatments.

Statistics:

  • 99 human tumour samples were used to develop and test SAVANA.
  • SAVANA achieved a high degree of accuracy in detecting structural variants and copy number aberrations, outperforming standard analysis tools.
  • The algorithm's average processing time was significantly faster than existing methods, making it suitable for clinical use.
  • SAVANA's results were highly consistent with Illumina sequencing data, demonstrating its reliability.
  • 10 clinical partners from various institutions collaborated with researchers at EMBL-EBI and Genomics England to develop and test SAVANA.

Sources:

  • SAVANA uses a machine learning algorithm to identify cancer-specific structural variations and copy number aberrations (Source: Nature Methods)
  • EMBL-EBI and Genomics England researchers developed and tested SAVANA across 99 human tumour samples (Source: European Bioinformatics Institute)
  • SAVANA provides accurate and reliable genomic data for clinicians to make informed decisions (Source: Greg Elgar, Director of Sequencing R&D at Genomics England)
  • SAVANA has been used to study osteosarcoma and has provided novel insights into how the disease evolves and progresses (Source: Isidro Cortes-Ciriano, Group Leader at EMBL-EBI)
  • SAVANA has the potential to improve diagnostic accuracy and support personalized cancer treatments (Source: Carolin Sauer, Postdoctoral Fellow at EMBL-EBI)
  • The UK is investing in genomic sequencing technologies as part of the NHS Genomic Medicine Service (Source: Genomics England)
  • Funding for the SAVANA project was provided by various institutions, including EMBL, Wellcome Trust, and Cancer Research UK (Source: Funding Acknowledgments)

Read more